Member Info for stocksaint

I think you'll find nothing gets announced at all, until delayed results in December, when we'll see Gino's first presentation to investors as well, in the runup to next year's cash call...

More like 0.7p

Pure fantasy talk from OGM. Next for this is crushing results in November and December (with virtually bugger all sales). Though potential trading opportunity coming on horizon as GDR gets closer to FDA for AIHL (though with risk of another cash call if FDA approval doesn't get announced for months into 2025).

Not to do with the fact they said lab testing for stroke test as preference then Gloria?

And not to do with the fact they don't have a full NICE-type recommendation on AIHL in ANY jurisdiction of the world yet?

Interesting how the people who were adamantly forecasting sales in September have gone pretty quiet.

Perhaps it's trending towards zero. After all, dog sxit isn't worth a lot is it.

Yeah Gloria, and this info. is all so NEW. And it's only 6 years since GDR first started trialing the AIHL test in a hospital!

"unless they can start pulling sales contracts out of a big hat!"

Roger, surely you mean unless they can do another fund raise? After all, they do one almost every year anyway.

Maybe some brokers just are ready with us later than others??? It might explain why I got an email from my broker out of the blue in mid-July saying they were ready.

Guess I should of said "new new CEO" to refer to Gino in the penultimate line. lol

"Why did the Chair recently spend 30k of his own money if he didn't think medium/ long term his investment would blossom?"

My view is that this was to renew confidence after the surprise early departure of the new CEO. How can anyone trust/have confidence in anything Cheek said seeing as he's gone, and he quit so early and abruptly?

And the new CEO has said very little since being appointed. If no news through October, this bound to be below the placing price.

I think they will issue an RNS when they actually file the FDA application

Seems unlikely to me when they already released 12th of August RNS reporting first sales of stroke product.

Looks like the rampers have gone to ground. Maybe some traders will move back in when it hits 1.5p-1.6p though.

Looking at the chart, it evident to even the dumbest person that this should hit 1.6p very shortly.

If they were to announce 3 or 4 hospitals in continental Europe had begun to use AIHL for routine use, this would be progress. But would hardly be significant in terms of the company's operating position. They could easily announce nothing at all in terms of sales for the remainder of the year. If no news, share price could easily drop below 1p by end of September. The 1.5-1.7p support may not necessarily be that strong.

As I understand not for research purposes but for demos by distributors. However, most/all European countries require NICE-type approvals before you get meaningful sales anyway. (Spain might be a bit of an exception to that rule based on previous marketing efforts from GDR).

So from what I can tell Eureka is just quoting from an old Cheek presentation about potential AIHL sales. Eureka is not claiming that GDR told him there were going to be significant sales of AIHL in September. (and Cheek is long gone anyway. lol)

And there haven't been any "trials" going on recently in Continental Europe. This was all just comments on the back of supplying some demo kit to distributors in Europe. As I said, there was an actual trial in Greece some years ago for AIHL, but it didn't lead to sales.

Eureka, do you realise that each European country also has the equivalent of NICE? So lots more hoops to jump through.

Can you name any of these supposed pilots for AIHL that are currently going on in Europe?

(I know there was definitely one in Greece done a few years ago.)

They already did an RNS reporting the "first UK commercial sales" from the stroke test kit on 12th of August (but only worth £100k), so do you mean there will be further "non-significant" sales reported in September?

Another question, why do think the European accreditation will allow them to "penetrate" the market for the stroke product in other European countries?

They got the same for AIHL years ago and it's led to nothing so far (apart from a trial at a hospital in Greece a few years ago).